Longaevus Technologies

Longaevus Technologies

Approaching Longevity From All Angles

Longaevus Technologies is a private research organisation with laboratories based in The United Kingdom that explores new and diverse pathways to healthy longevity.

Our international team of renowned scientists, academics and industry experts brings experience from all over the globe. Our team works diligently in order to achieve our goal: the all-encompassing reversal of ageing.

Who we are
Perspectives

Perspectives on
Ageing

The need for ageing interventions is more critical than ever. By 2050, the population over 60 years old is expected to nearly double, from 12% to 22%, leading to a 2x increase in global spending on age-related disease treatment.

Currently, there are no approved treatments for the complex process of ageing, and existing treatments merely scratch the surface by addressing symptoms . However, a healthspan revolution is underway. Thanks to advancements in OMICS approaches, AI, and cutting-edge lab techniques, we're now on the verge of uncovering the very root causes of ageing.

Unlike conventional practices, Longaevus embraces a comprehensive approach. We believe that to effectively combat ageing, we must unite various fields of science and research to address the collective root causes. It's time for a new era in human healthspan.

Longaevus approaches the problem of
ageing from 5 different directions:

Our research has shown that it is possible to first identify multiple ageing factors, then use interventions to counteract these factors and increase the lifespan of model organisms. Relevant studies have also demonstrated that the enhancement of particular genes’ expressions can cause organisms such as drosophila to live 2.5 times longer. Additionally, research on the DNA of the grey whale and Brandt’s bat has yielded significant results uncovering factors that affect their longevity. Following this multidirectional approach, we believe that we will achieve our goal to bring humanity towards a state of great age – or in latin, longaevus.

Approach
Pipeline

Integrated Venture Acceleration

Ageing is a complex and intricate interplay of many different pathological networks. Our multidirectional approach permits us to implore all aspects of available ageing research and provide empirically grounded conclusions. This approach allows us to experimentally validate interventions that have a potential for clinical development. Through the use of our five-step pipeline, we believe we can introduce desperately needed ageing interventions to the world in a timely manner.

Advisory Board

Viktor Korolchuk

Viktor Korolchuk, PhD

Molecular Biologist and Member of British Society for Research on Ageing, Scientific Advisor

John Sedivy

John Sedivy, PhD

Gerontologist, Professor of Biology and a Professor of Medical Science, Scientific Advisor

Alan R. Parrish

Alan R. Parrish, PhD

Professor in Medical Pharmacology and Physiology, Scientific Advisor

Alexander Fedintsev

Alexander Fedintsev, PhD

Biogerontologist, Scientific Advisor

Jing Yang

Jing Yang, PhD

Professor of Pharmacology, Scientific Advisor

Plamena R. Angelova

Plamena R. Angelova, PhD

Cell biophysicist, Scientific Advisor

Collin Y. Ewald

Collin Y. Ewald, PhD

Molecular Biologist and a president of the Swiss Society for Aging Research, Scientific Advisor

Helen L. Birch

Helen L. Birch, PhD

Professor in Skeletal Tissue Dynamics, Scientific Advisor

Longaevus Team

Ivan Morgunov

Ivan Morgunov

Founder

Alexey Moskalev

Alexey Moskalev

Founder

Dmitry Klokov

Dmitry Klokov

Molecular Biologist, Senior Researcher

Anna Vakhrusheva

Anna Vakhrusheva

Entrepreneur in residence

Olga Borysova

Olga Borysova

Entrepreneur in residence

Faya Movchan

Faya Movchan

Computational Neuroscientist, Lab Manager

Rakhan Aimbetov

Rakhan Aimbetov

Analyst

Samira Kaziakhmedova

Samira Kaziakhmedova

Analyst

Sherif Idriss

Sherif Idriss

Entrepreneur in residence

Francesca Lugarini

Francesca Lugarini

Entrepreneur in residence